Development of new products

Cryolijm-SQ studies

Project leader: Dirk de Korte PhD 

From 2008 cryolijm-SQ, a fibrin glue of single donor plasma which Sanquin has started to produce as an alternative for autologous or pooled plasma fibrin glues is produced in a routine setting. In 2009 the Department of Transfusion Monitoring (TraM) started a formal stability study to officially confirm the two-year storage life of cryo-SQ.
The formal cryolijm-SQ stability study was completed in January 2012; all tested samples met the predetermined requirements.

To be able to produce autologous cryolijm and because of the interest in cryolijm-SQ from foreign countries, the production of cryolijm-SQ from whole blood derived plasma and fresh apheresis plasma was validated and approved in 2011. The shelf life study of whole blood derived plasma continued in 2012 and will be completed in 2013.

Austrian whole blood derived inline filtered plasma units could be used for the production of cryolijm-SQ for the European market. The validation was initiated in 2011 and completed in 2012: all tested samples met the predetermined requirements. Also for cryolijm-SQ produced from Austrian whole blood derived inline filtered plasma a shelf life study was initiated in 2012 and will be completed in 2014.

Sanquin is creating the possibility to transfer the technology of cryolijm-SQ production to foreign countries. A training program was developed and is practically ready. It has to be fine tuned at the time the first training courses are scheduled.

Other studies in correlation to cryolijm-SQ are:

Key publication

Diluted thrombin leads to an extended clotting time of cryolijm-SQ. Undiluted thrombin leads to a clotting time of cryolijm-SQ within 10 seconds.
Figure 1: Diluted thrombin leads to an extended clotting time of cryolijm-SQ. Undiluted thrombin leads to a clotting time of cryolijm-SQ within 10 seconds.

Last edited on: 12 September 2014